Design of iodine-lithium-α-dextrin liquid crystal with potent antimicrobial and anti-inflammatory properties

Current Pharmaceutical Design

Volumn 15, Issue 11, 2009, Pages 1172-1186

  Davtyan, Tigran K ^a   Mkhitaryan, Levon M ^b   Gabrielyan, Emil S ^c  

^a Armenicum Research Centre Yerevan   (Armenia)

^b YEREVAN STATE MEDICAL UNIVERSITY   (Armenia)

^c Armenian Ministry of Health   (Armenia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CYCLODEXTRIN; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; ARMENICUM; BETA 1,3 GLUCAN; BETA 1,6 GLUCAN; CARBOXYMETHYLDEXTRAN; DEXTRAN DERIVATIVE; DEXTRAN SULFATE; DEXTRIN; DIMETHYLAMINOETHYLDEXTRAN; HEMOGLOBIN; INSULIN; IODINE; IODINE LITHIUM ALPHA DEXTRIN; IODOPHOR; LITHIUM; POLYMER; POLYSACCHARIDE; POLYURETHAN; POLYVINYL ALCOHOL; POVIDONE; POVIDONE IODINE; SURAMIN; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADJUVANT THERAPY; ALZHEIMER DISEASE; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTIVIRAL ACTIVITY; ARTHRALGIA; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BIPOLAR DISORDER; BRAIN INJURY; BREAST FIBROSIS; CARCINOGENICITY; CHILL; CLINICAL TRIAL; DEGENERATIVE DISEASE; DIABETES MELLITUS; DIET THERAPY; DIETARY INTAKE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG FEVER; DRUG FORMULATION; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG SYNTHESIS; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBRYOTOXICITY; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUNTINGTON CHOREA; HYPOTHYROIDISM; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATORY DISEASE; IODINE DEFICIENCY; LD 50; LEUKOCYTE COUNT; LIQUID CRYSTAL; LOW DRUG DOSE; MALAISE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; OBESITY; OLIGOMENORRHEA; OVARY POLYCYSTIC DISEASE; PARKINSON DISEASE; PATIENT COMPLIANCE; PHLEBITIS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; STEREOCHEMISTRY; SWEAT GLAND DISEASE; TAUOPATHY; TOXIC HEPATITIS; VIRUS INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIVIRAL AGENTS; DEXTRINS; HIV INFECTIONS; HUMANS; IMMUNOLOGIC FACTORS; IODINE COMPOUNDS; LIQUID CRYSTALS; LITHIUM COMPOUNDS; MICROBIAL SENSITIVITY TESTS;

EID: 65649112441     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787846829     Document Type: Review

References (137)

1. Casanova JL, Abel L. Inborn errors of immunity to infection: the rule rather than the exception. J Exp Med 2005; 202: 197-201.
2. Fleischer W, Reimer K. Povidone-iodine in antisepsis - State of the art. Dermatology 1997; 195 (Suppl 2): 3-9.
3. Gottardi W. Iodine and iodine compounds. In: Block SS Ed, Disinfection, Sterilization and Preservation. Philadelphia: Lea & Febiger 1983; 183-96.
4. Kunisada T, Yamada K, Oda S, Hara O. Investigation on the efficacy of povidone-iodine against antiseptic-resistant species. Dermatology 1997; 195(Suppl 2): 14-8.
5. Schreier H, Erdos G, Reimer K, Koing B, Koing W, Fleischer W. Molecular effects of povidone-iodine on relevant microorganisms: an electron microscopic and biochemical study. Dermatology 1997; 195(Suppl 2): 111-6.
6. Saenger W, Noltemeyer M, Betzel Ch. Cyclodextran polyiodide inclusion complex as models for starch-iodine. In: Zalewski RI, Skolik JJ, Ed, Natural products Chemistry. Elsevier Science Publishers: Amsterdam 1985; pp. 397-405.
7. Gessler K, Uson I, Takaha T, Krauss N, Smith SM, Okada S, et al. V-amylose at atomic resolution: X-ray structure of a cycloamylose with 26 glucose residues (cyclomaltohexaicosaose). Proc Natl Acad Sci USA 1999; 96: 4246-51.
8. Nimz O, Gebler K, Uson I, Saenger W. An orthorhombic crystal from of cyclomaltohexaicosaose, CA26.32.59 H2O: Comparison with the triclinic form. Carbohydr Res 2001; 336: 141-53.
9. Yu X, Houtman C, Atalla RH. The complex of amylose and iodine. Carbohydr Res 1996; 292: 129-41.
10. Noltemeyer M, Saenger W. Structural chemistry of liner acylodextrin- polyiodide complexes: X-ray crystal structures of (acylodextrin) 2·LiI3·I2·8H2O and (a-cylodextrin)2·Cd0.5·I5·7H2O. Models for the blue amylose-iodine complex. J Am Chem Soc 1980; 102: 2710-22.
11. Noltemeyer M, Saenger W. X-ray studies of linear polyidodide chains in a α-cylodextrin channels and a model for the starchiodine complex. Nature 1976; 259: 629-32.
12. Nimz O, Gebler K, Laettig S, Welfle H, Sheldrick GM, Saenger W. X-ray structure of the cycloamylose triiodide inclusion complex provides a model for amylose-iodine at atomic resolution. Carbohydr Res 2003; 338: 977-86.
13. II'in AI. Armenicum - a new drug with antiviral and antibacterial properties. In: Gabrielyan ES, Ed. Armenicum. Experimantal studies. Gitutyun, Nat Acad Sci Yerevan: Armenia 2000; pp. 7-15.
14. Lyoo WS, Yeum JH, Ghim HD, Park JM, Lee SJ, Kim JH, Shin DY, Lee JW. Effect of the molecular weight of poly(vinil alcohol) on the water stability of a syndiotactic poly(vinil alcohol)/iodine complex film. Colloid Polym Sci 2003; 281: 416-22.
15. Reimer K, Fleischer W, Brogmann B, Schreier H, Burkhard P, Lanzendorfer A, et al. Povidone-ionie liposomes - an overview. Dermatology 1997; 195(Suppl 2): 93-9.
16. Reimer K, Vogt PM, Broegmann B, Hauser J, Rossbach O, Kramer A, et al. An innovative topical drug formulation for wound healing and infection treatment. Dermatology 2000; 201: 235-41.
17. Wutzler P, Sauerbrei A, Klocking R, Brogmann B, Reimer K. Virucidal activity and cytotoxicity of the liposomal formulation of povidone-iodine. Antiviral Res 2002; 54: 89-97.
18. Wutzler P, Sauerbrei A, Klocking R, Burkhard P, Schacke M, Thust T, et al. Virucidal and chlamydicidal activities of eye drops with povidone-iodine liposome complex. Ophthalmic Res 2000; 32: 118-25.
19. Harbison MA, Hammer SM. Inactivation of human immunodeficiency virus by betadine products and chlorhexidine. J Acquir Immune Defic Syndr 1998; 2: 16-20.
20. Highsimith F, Xue H, Chen X, Benade L, Owens J, Shanbrom E, Drohan W. Iodine-mediated inactivation of lipidand nonlipid-enveloped viruses in human antithrombin III concentrate. Blood 1995; 86: 791-6.
21. Shikani AH, Clair M, Domb A. Polymer-iodine inactivation of the human immunodeficiency virus. J Am Coll Surg 1996; 183: 195-200.
22. Abraham GE. The safe and effective implementation of orthoiodo-supplementation in medical practice. Orig Internist 2004; 11(1): 17-36.
23. Abraham GE. The historical background of the iodine project. Orig Internist 2005; 12(2): 57-66.
24. Kelly FC. Iodine in medicine and pharmacy since its discovery 1811-1961. Proc R Soc Med 1961; 54: 831-36.
25. Hollowell J, Staehling N, Hannon W, Flanders D, Gunter E, Maberly G. Iodine nutrition in the United States. Trends and public health implications: Iodine excretion data from national health and nutrition examination surveys I and III (1971-1974 and 1988-1994). J Clin Endocrinol Metab 1998; 83: 3401-08.
26. Dunn JT. What's happening to our iodine? J Clin Endocrinol Metab 1998; 83: 3398-400.
27. Cann S, Netten J, and Netten C. Hypothesis: Iodine, selenium and the development of breast cancer. Cancer Causes Control 2000; 11: 121-7.
28. Stadel B. Dietary iodine and risk of breast, endometrial, and ovarian cancer. Lancet 1976; 1: 890-7
29. Nagataki S, Shizume K, Nakao K. Thyroid function in chronic excess iodide ingestion: Comparison of thyroidal absolute iodine uptake and degradation of thyroxine in euthyroid Japanese subjects. J Clin Endocrinal 1967; 27: 638-47.
30. Konno N, Yuri K, Miura K, Kumagai M, Murakami S. Clinical evaluation of the iodide/creatinine ratio of casual urine samples as an index of daily iodide excretion in a population study. Endocrine J 1993; 40: 163-9.
31. Abraham GE, Flechas JD, Hakala JC. Orthoiodosupplementation: Iodine sufficiency of the whole human body. Orig Internist 2002; 9(4): 30-41.
32. Abraham GE, Flechas JD, Hakala JC. Optimum levels of iodine for greatest mental and physical health. Original Internist 2002; 9(3): 1-20
33. Abraham GE. The concept of orthoiodosupplementation and its clinical implications. Orig Internist 2004; 11(2): 29-38.
34. Brown-Grant K. Extrathyroidal iodide concentrating mechanisms. Physiol Rev 1961; 41: 189-213.
35. Abraham GE. Serum inorganic iodide levels following ingestion of a tablet form of Lugol solution: Evidence for an enterohepatic circulation of iodine. Orig Internist 2004; 11(3): 29-34.
36. Wada A, Yokoo H, Yanagita T, Kobayashi H. Lithium: Potential therapeutics against acute brain injuries and chronic neurodegenerative diseases. Pharmacol Sci 2005; 99: 307-21.
37. Jope RS. Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry 1999; 4: 117-28.
38. Hallcher LM, Sherman WR. The effects of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. J Biol Chem 1980; 255: 10896-901.
39. Grimes CA, Jope RS. The multi-faceted roles of glycogen synthase kinase-3β in cellular signaling. Prog Neurobiol 2001; 65: 391-426.
40. Jope RS. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 2003; 24: 441-3.
41. Pap M, Cooper GM. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem 1998; 273: 19929-32.
42. Wei H, Leeds PR, Qian Y, Wei W, Chen R, Chuang D. β-amyloid peptide-induced death of PC12 cells and cerebellar granule cell neurons is inhibited by long-term lithium treatment. Eur J Pharmacol 2000; 392: 117-23.
43. Watcharasit P, Bijur GN, Zmijewski JW, Song L, Zmijewska A, Chen X, et al. Direct, activating interaction between glycogen synthase kinase-3β and p53 after DNA damage. Proc Natl Acad Sci USA 2002; 99: 7951-5.
44. Song L, De Sarno P, Jope RS. Central role of glycogen synthase kinase-3β in endoplasmic reticulum stress-induced caspase-3 activation. J Biol Chem 2002; 277: 44701-08.
45. Ren M, Senatorov VV, Chen RW, Chuang DM. Postinsult treatment with lithium reduces brain damage and facilitates neurological recovery in a rat ischemia/reperfusion model. Proc Nat Acad Sci USA 2003; 100: 6210-15.
46. Centeno F, Mora A, Fuentes JM, Soler G, Claro E. Partial lithium associated protection against apoptosis induced by C2-ceramide in cerebellar granule neurons. Neuroreport 1998; 9: 4199-203.
47. Chuang DM, Chen RW, Chalecka-Franaszek E, Ren M, Hashimoto R, Senatorov V, et al. Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord 2002; 4: 129- 36.
48. Song L, Zhou T, Jope RS. Lithium facilitates apoptotic signaling induced by activation of the Fas death domain-containing receptor. BMC Neurosci 2004; 5: 20.
49. Focosi D, Azzara A, Kast RE, Carulli, G, Petrini M. Lithium and hematology: established and proposed uses. J Leukoc Biol 2009; 85:
50. Lieb J. The immunostimulating and antimicrobial properties of lithium and antidepressants. J Infec 2004; 49: 88-93.
51. Harvey BH, Meyer CL, Galliccbio VS, Manji HS. Lithium salts in AIDS and AIDS-related dementia. Psychopharmacol Bull 2002; 36: 5-26.
52. Everall IP, Bell C, Mallory M, Langford D, Adame A, Rockestein E et al. Lithium ameliorates HIV-gp120-mediated neurotoxicity. Mol Cell Neuorosci 2002; 21: 493-501.
53. Lieb J. Lithium and antidepressants: inhibiting eicosanoids, stimulating immunity, and defeating microorganisms. Med Hypotheses 2002; 59: 429-32.
54. Lieb J. Eicosanoids: the molecules of evolution. Med Hypotheses 2001; 56: 686-93.
55. Harotti K, Yoshida T, Nakashima Hl. Synthesis of sulfonated amino-polysacharides having anti-HIV and blood anticoagulant activities. Carbohydr Res 1998; 312(1-2): 1-8.
56. Witvrow M, De Clercq E. Sulfated polysaccharides extracted from sea algae as potential antiviral drugs. Gen Pharmacol 1997; 29 (4): 497-511.
57. Heibert LM, Wice SM, Jagues LB. Orally administered dextran sulfate is absorbed in HIV-positive individuals. J Lab Clin Med 1999; 133(2): 161-70.
58. Jagodrinshi PP, Trezeciak WH. High molecular mass dextran sulfate increases expression of HIV-1 coreceptor CCR-5 in macrophage - monocytes in culture. Acta Biochem Pol 1995; 45(1): 241-4.
59. Jagodzinski PP, Trzeciak WH. High molecular weight dextran sulfate increases the activity of NF-kappab regulated promoter in monocyte macrophages. Microbiol Immunol 1990; 2: 187-9.
60. Mori H, Otake T, Oishi J, Kurimura T. Characterization of human immunodeficiency virus type 1 resistant to modified cyclodextrin sulphate (mCDS71) in vitro. Antivir Chem Chemother 1999; 1: 15-21.
61. Pearce-Pratt R, Phillirs DM. Sulfated polysacharides inhibit lymphocyte- to-epithelial transmission of human immunodeficiency virus. Bid Reprod 1996; 54 (1): 173-182.
62. Schols D, Pauwels R, Desmyter J, De Clercq E. Dextran sulphate and other polyanionic anti-HIV compounds specifically infected with HIV-1.Virology 1990; 2: 556-61.
63. Termeer CC, Weiss GM, Schorf E, Vanscheidt W, Simon JC. The low molecular weight Dextran 40 inhibids the adhesion of T- lymphocytes to endothelial cells. Clin Exp Immunol 1998; 114 (3): 422-6.
64. Taylor DL, Brennan CG. Potent inhibition of human immunodeficiency virus by MDL 10128, a novel sulphonic acid polymer. J Antiviral Res 1995; 2: 159-73.
65. Aleksanyan YuT, Hakobyan IS, Babayan GR. Bactericidal activity of the Armenicum preparation. Gabrielyan ES Armenicum, Experimental studies. Yerevan: Gitutyun, Nat Acad Sci Armenia 2000; pp. 81-7.
66. Davtyan TK, Hakobyan IS, Manukyan HA, Avetisyan SA, Gabrielyan ES. Phagocytosis and Oxidative Burst down-modulation by potent microbicide lithium-iodophore. J Nat Sci 2004; 2: 22-30.
67. Davtyan TK, Hakobyan IS, Muradyan RE, Hovhannisyan HG, Gabrielyan ES. Evaluation of amino acids as mediators for the antibacterial activity of iodine-lithium-a-dextrin in vitro and in vivo. J Antimicrob Chemother 2007; 59(6): 1114-22
68. Klebanoff SJ. Oxygen metabolites from phagocytes. In: Gallin JI, Snyderman R Ed. Basic Principles and Clinical Correlates. Philadelphia: Lippincott Williams & Wilkins 1999; 721-68.
69. Segal AW, Abo A. The biochemical basis of the NADPH oxidase of phagocytes. Trends Biochem Sci 1993; 18: 43-7.
70. Hampton MB, Kettle AJ, Winterbourn CC. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood 1998; 92: 3007-17.
71. Klebanoff SJ. Myeloperoxidase: friend or foe. J Leukoc Biol 2005; 77: 587-97.
72. Hazen SL, Hsu FF, Muller DM. Human neutrophils employ chloride gas as an oxidant during phagocytosis. J Clin Invest 1996; 98: 1283-9.
73. Winterbourn CC. Biological reactivity and biomarkers of the neutrophil oxidant, hypochlorous acid. Toxicology 2002; 181-182: 223-7.
74. Rosen H, Crowley JR, Heinecke JW. Human neutrophils use the myeloperoxidase-hydrogen peroxide-chloride system to chlorinate but not nitrate bacterial proteins during phagocytosis. J Biol Chem 2002; 277: 30463-8.
75. Chapman ALP, Hampton MB, Senthilmohan Rl. Chlorination of bacterial and neutrophil proteins during phagocytosis and killing of Staphylococcus aureus. J Biol Chem 2002; 277: 9757-62
76. Arlandson M, Decker T, Roongta VA. Eosinophil peroxidase oxidation of thiocyanate: characterization of major reactions and a potential sulfhydril-targeted. J Biol Chem 2001; 276: 215-24.
77. Furtmuller PG, Burner U, Obinger C. Reaction of myeloperoxidase compound I with chloride, bromide, iodide and thiocyanate. Biochemistry 1998; 37: 17923-30.
78. Segal AW, Garcia RC, Harper AM. Iodination by stimulated neutrophils. Studies on its stoichiometry, subcellular localization and relevance to microbial killing. Biochem J 1983; 210: 215-25.
79. Klebanoff SJ. Iodination of bacteria: a bactericidal mechanism. J Exp Med 1967; 126: 1063-78.
80. Root RK, Stossel TP. Myeloperoxidase-mediated iodination by granulocytes. Intracellular site of operation and some regulating factors. J Clin Invest 1974; 53: 1207-15.
81. Thomas EL, Fishman M. Oxidation of chloride and thiocyanate by isolated leukocytes. J Biol Chem 1986; 261: 9694-702.
82. van Dalen CJ, Whitehouse MW, Winterbourn CC. Thiocyanate and chloride as competing substrates for myeloperoxidase. Biochem J 1997; 327: 487-92.
83. Avetisyan SA, Hakobyan VP, Davtyan TK. The iodophore (iodine-lithium- a-dextrin) modulation of the action of sodium thiosulfate on the respiratory burst of granulocytes and monocytes in patients with familial Mediterranean fever. Med Sci Armenia 2005; 46: 3-9.
84. Nagl M, Hess MW, Pfaller K. Bactericidal activity of micromolar N-chlorotaurine: evidence for its antimicrobial function in the human host defence system. Antimicrob Agents Chemother 2000; 44: 2507-13.
85. Marcinkiewicz J, Mak M, Bobek M. Is there a role of taurine bromamine in inflammation? Interactive effects with nitrite and hydrogen peroxide. Inflamm Res 2005; 54: 42-9.
86. Learn DB, Fried VA, Thomas EL. Taurine and hypotaurine content of human leukocytes. J Leukoc Biol 1990; 48: 174-82.
87. Gaut JP, Yeh GC, Tran HD. Neutrophils employ the myeloperoxidase system to generate antimicrobial brominating and chlorinating oxidants during sepsis. Proc Natl Acad Sci USA 2001; 98: 11967-86.
88. Henderson JP, Byun J, Williams MV. Production of brominating intermediates by myeloperoxidase. J Biol Chem 2002; 277: 24049-56.
89. Reeves EP, Nagl M, Godovac-Zimmermann J. Reassessment of the microbicidal activity of reactive oxygen species and hypochlorous acid with reference to the phagocytic vacuole of the neutrophil granulocyte. J Med Microbiol 2003; 52: 643-51.
90. Baura M, Liu Y, Quinn MR. Taurine chloramine inhibits inducible nitrite oxide synthase and TNF-a gene expression in activated alveolar macrophages: decreased NF-κB activation and IkB kinase activity. J Immunol 2001; 167: 2275-81.
91. Park E, Alberti J, Quinn MR. Taurine chloramines inhibits the production of superoxide anion, IL-6 and IL-8 in activated human polymorphonuclear leukocytes. Adv Exp Med Biol 1998; 442: 177-83.
92. Alexanyan YuT, Kamalyan LA, Melik-Andreasyan GG. Study of the antiviral action of Armenicum in the experiment. In: Gabrielyan ES Ed. Armenicum. Experimantal studies. Gitutyun, Nat Acad Sci Yerevan, Armenia 2000; 49-69.
93. Davtyan TK, Hakobyan IS, Gabrielyan ES. CD4 and CD14 receptors down-modulation by potent microbicide lithium-Iodophore. 13th International symposium on HIV and emerging infectious diseases. Toulon: France 2004; 177.
94. Davtyan TK, Hakobyan IS, Mkhitaryan LM, Gabrielyan ES. Antiinflammatory properties and CD4, CD14 receptors downmodulation by potent microbicide lithium-Iodophore. International J Immunoreabil 2004; 6(2); 261.
95. Davtyan.TK. Immunity to viruses and retroviruses. Virus evolution and viral quasispecies emergence. Taipei fall workshop on nonlinear and complex systems. Taipei: Taiwan 2003.
96. Gabrielyan ES, Mkhitaryan LM. Analogues and prototypes of Armenicum'. In: Gabrielyan ES, Mkhitaryan LM Ed. Armenicum: Experimental and Clinical Studies, Yerevan: Gitutyun, Nat Acade Sci Armenia 2001; pp. 7-32.
97. 131I-Armenicum in rabbits. i In Gabrielyan ES, Mkhitaryan LM Ed, Armenicum: Experimental and Clinical Studies, Yerevan: Gitutyun, National Academical Science Armenia 2001; 33-47.
98. Panossian AG, Hovhannisyan AS, Tirakian MR, Sarkissian HA, Mkhitaryan, LM, Gabrielyan ES. Pharmacokinetics of iodide anion at intravenous administration of Armenicum in rabbits and human volunteers. In: Gabrielyan ES Ed. Armenicum. Experimantal studies. Gitutyun, Nat Acad Sci Yerevan: Armenia 2000; 33-48.
99. Muradyan RE, Arsenyan FH, Stepanyan HM, Garibjanyan BT, Gabrielyan ES. Experimental studies of toxicity of antiviral drug Armenicum. In: Gabrielyan ES Ed. Armenicum. Experimantal studies. Gitutyun, Nat Acad Sci Yerevan, Armenia 2000; pp. 17-31.
100. Nerssesyan AK, II'in AI. The study of the antimutagemic activity of Armenicum. In: Gabrielyan ES Ed. Armenicum. Experimantal studies. Gitutyun, Nat Acad Sci Yerevan, Armenia 2000; pp. 129- 35.
101. Johnson A., Day ED, Pressman D. The effect of iodination on antibody activity. J Immunol 1960; 84: 213-20
102. Pressman D, Radzimski G. Increased precipitation of antibody as a result of iodination. J Immunol 1962; 89: 367-76.
103. Koshland MR, Englberger FM, Gaddone SM. The effect of iodination on the binding of haptene to arsonic antibody. J Immunol 1962; 89: 517-24.
104. Lepow IH, Patrick RA. Cleavage products of components of human complement. J Immunol 1970; 102: 1340.
105. Polley MJ. Enhancement of hemolytic complement activity by treatment of human serum with iodine. J Immunol 1971; 107: 1493-5.
106. Ngan B-Y, Gelfand EW, Minta JO. A simple one-step hemolytic assay for C2 with C2-deficient human serum. J Immunol 1977; 118: 736-41.
107. Alexanyan YT, Davtyan TK, Il'in AI. Study of the immunotropic activity of Armenicum. In: Gabrielyan ES Ed. Armenicum. Experimantal studies. Gitutyun. Nat Acad Sci Yerevan: Armenia 2000; pp. 89-103
108. Davtyan TK. Report on the experimental studies of Armenicum immunomodulating activity. In: Gevorkyan LA Ed, Armenicum: Experimental studies. Yerevan: Gitutyun: Nat Acad Sci Armenia 2002; pp. 1-72.
109. McClain DA, Wang JL, Edelman GM. The effects of sodium metaperiodate on T and B lymphocytes. Cell Immunol 1979; 15: 287-92.
110. Novogrodsky A, Stenzel KH, Rubin AL. Stimulation of human peripheral blood lymphocytes by periodate, galactose oxidase, soybean agglutmin, and peanut agglutinin: differential effects of adherent cells. J Immunol 1977; 118: 852-63.
111. Novogradsky A. Induction of lymphocyte cytotoxicity by modification of the effector or target cells with periodate or with neuraminidase and galactose oxidase. J Immunol 1975; 114: 1089-94.
112. Grenounou M, Agneray J. Induction of suppressor cells by sodium periodate: the opposite expression of periodate-induced lymphocyte activation in spleen cells of normal and nude mice. Immunology 1979; 37: 53-8.
113. Galanaud P, Crevon MC, Grenounou M, Agneray J, Dormont J. Sodium periodate-induced suppressor T cells of the human in vitro antibody response. Cell Immunol 1980; 51: 85-90.
114. Pietsch.J, Meakins JL. Complication of povodine-iodine absorption in topically treated burn patients. Lancet 1976; 1: 280-4.
115. Ninnemann JL, Stein MD. Suppressor cell induction by povidoneiodine: in vitro demonstration of a consequence of clinical burn treatment with betadine. J Immunol 1981; 126: 1905-07.
116. Caturegli P, Hejazi M, Suzuki K, Dohan O, Carrasco N, Kohn LD, et al. Hypothyroidism in transgenic mice expressing IFN-γ in the thyroid. Proc Natl. Acad Sci USA 2000; 97: 1719-24.
117. Sharma RB, Alegria JD, Talor MV, Rose NR, Caturegli P, Burek LC. Iodine and IFN-γ synergistically enhance intercellular adhesion molecule 1 expression on NOD.H2h4 mouse thyrocytes. J Immunol 2005; 174: 7740-5.
118. Roebuck KA, Finnegan A. Regulation of intercellular adhesion molecule-1 (CD54) gene expression. J Leukocy Biol 1999; 66: 876-88.
119. Davtyan TK, Gukassyan VZ, Mkhitaryan, LM, Gabrielyan ES. Influence of Armenicum on proliferation of lymphocytes, production of cytokines and soluble markers of immune activation. In: Gabrielyan ES, Mkhitaryan LM Eds. Armenicum: Experimental and Clinical studies. Yerevan: Gitutyun, Nat Acad Sci Armenia 2001; 84-105.
120. Davtyan TK, Avetisyan SA, Hakobyan GS, Manukyan AM, Poghosyan DA. Flow cytometry of the phagocytosis of granulocytes and monocytes at Familial Mediterranean Fever. Med Sci Armenia 2004; 44: 44-9.
121. Davtyan TK, Avetisyan SA, Hakobyan GS, Manukyan HA, Poghosyan DA, Seferian NH. Granulocytes and monocytes phagocytosis in patients with Familial Mediterranean fever. In vitro pharmacological modulation. J Nat Sci 2005; 4: 25-33.
122. Avetisyan SA, Hakobyan GS, Davtyan TK. Modulation of endotoxin- induced respiratory splash of granulocytes and monocytes in patients with familial Mediterranean fever by iodine-lithium-adextrin and sodium thiosulfate. Patol Fiziol Eksp Ter 2006; 1: 11-3.
123. Avetisyan SA, Hakobyan VP, Davtyan TK. The effect of colchicine and iodine-lithium-α-dextrin on the phagocytosis of granulocytes and monocytes in patients with familial Mediterranean fever. Exp Klin Pharm 2005; 68(5): 36-9.
124. Avetisyan SA. Pharmacological modulation of phagocytosis of granulocytes and monocytes in patients with familial Mediterranean fever. Exp Klin Pharm 2005; 68: 40-3.
125. Hakobyan VP,Avetisyan SA, Davtyan TK. The effect of colchicine on the spontaneous and induced respiratory burst of granulocytes and monocytes in patients with familial Mediterranean fever. Exp Klin Pharm 2005; 68: 43-6.
126. Davtyan TK, Mkrtchyan NR, Manukyan HA Avetisyan SA. Dexamethasone, colchicine and iodine-lithium-a-dextrin act differentially on the oxidative burst and endotoxin tolerance induction in vitro in patients with Behçet's disease. Int Immunopharm 2006; 6: 396-407.
127. Davtyan TK, Hakobyan GS, Avetisyan SA, Harutyunyan VA. Engaging anti-inflammatory mechanisms and triggering inflammatory effectors apoptosis during Familial Mediterranean fever attack. Inflamm Res 2008; 57: 65-74.
128. Ho DD, Huang Y. The HIV-1 vaccine race. Cell 2002; 110: 135-8.
129. Allen TM, Kelleher AD, Zaunders J, Walker BD. STI and beyond: the prospects of boosting anti-HIV immune responses. Trends Immunol 2002; 23: 456-60.
130. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003; 9: 727-8.
131. Mkhitaryan LM, Davtyan TK, Gabrielyan ES, Gevorkyanyan LA. Anti-HIV and anti-inflammatory action of iodine-lithium-α-dextrin is accompanied by the improved quality of life in AIDS patients. Int J Biotechnol 2007; 9(3/4): 301-17.
132. Steven G, Deeks B, Walker D. The immune response to AIDS virus infection: good, bad or both?' J Clin Invest 2004; 113(6): 808-10.
133. Bourinbaiar AS, Abulafia-Lapid R. Autoimmunity, alloimmunization and immunotherapy of AIDS. Autoimmune Rev 2005; 4: 403-9.
134. Hellestein MK. Subpopulation of long-lived and short lived T-cells in advanced HIV-1 infection. J Clin Invest 2003; 112: 956-66.
135. Silverstri G, Feinberg MB. Turnover of lymphocytes and conceptual paradigms in HIV infection. J Clin Invest 2003; 112: 821-4.
136. Hunt PW, Deeks SG, Rodriguez B, Valdez H, Shade SB, Abrams DI, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 2003; 17: 1907-191.
137. Silvestri G. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high level viremia. Immunity 2003; 18: 441-52.